Your genes may be working against your heart in ways doctors have not traditionally measured.
Deep within the human genome, a quiet efficiency can become a liability — and researchers at the University of Helsinki have now traced that liability to the heart. A new study reveals that people genetically predisposed to absorb cholesterol more effectively from food face an elevated risk of coronary artery disease, even when standard blood cholesterol measures appear manageable. The finding suggests that medicine's long reliance on a single number — LDL-C — may be leaving some patients unprotected, and that the future of heart care may lie in reading each person's biology more completely.
- A genetic trait that quietly pulls more cholesterol from food into the bloodstream is independently accelerating the buildup of arterial plaques in some patients, raising their risk of heart attack beyond what standard tests reveal.
- The discovery creates urgency for patients who have already survived acute coronary syndrome — a life-threatening emergency — and may still be undertreated despite following conventional statin therapy.
- Statins, the cornerstone of cholesterol treatment for decades, demonstrably improved outcomes in high-absorption patients, yet the Helsinki team warns they may not be sufficient to close the gap in risk.
- Biomarkers can already identify high cholesterol absorption efficiency, meaning the tools to act on this finding exist — the gap is in clinical practice, not technology.
- Researchers are pointing toward a dual-therapy approach — combining statins with intestinal cholesterol-blocking drugs — as a targeted intervention that could prevent first or repeat heart attacks in genetically vulnerable patients.
Your genes may be quietly working against your heart in ways that standard medical tests have never been designed to catch. Researchers at the University of Helsinki have found that people born with a genetically high efficiency for absorbing cholesterol from food face a significantly elevated risk of coronary artery disease — a risk that persists even after accounting for the cholesterol levels doctors routinely measure and treat.
Coronary artery disease develops as fatty plaques accumulate inside the arteries supplying the heart, narrowing them over time until blood flow is dangerously restricted. When blockage becomes severe, the result can be a heart attack or acute coronary syndrome — a medical emergency that can be fatal.
For decades, medicine has centered its response on LDL-C, the so-called bad cholesterol circulating in the blood. Statins, which block the liver's cholesterol production, have saved countless lives by lowering it. But Helena Gylling and her team found something the standard model misses: among patients who had already suffered acute coronary syndrome, those with high genetic absorption efficiency carried substantially greater coronary artery disease risk than those with low efficiency — a difference that held even when other known risk factors were controlled for.
The study confirmed that consistent statin use improved outcomes for these patients. Yet the researchers argue that for people with high absorption efficiency, statins alone may leave a dangerous gap. The solution they point toward is a more personalized approach: identifying high-absorption patients through existing biomarkers and adding intestinal cholesterol-blocking medications that work through a different mechanism than statins, providing complementary protection.
The broader implication is a shift away from one-size-fits-all cardiovascular care. For patients with the genetic misfortune of efficient cholesterol absorption, a targeted dual-therapy strategy could mean the difference between managed risk and a fatal cardiac event.
Your genes may be working against your heart in ways doctors have not traditionally measured. Researchers at the University of Helsinki have discovered that people born with an efficient capacity to absorb cholesterol from food face a higher risk of coronary artery disease—independent of the cholesterol levels that doctors routinely check and treat.
Coronary artery disease develops when fatty plaques accumulate inside the arteries feeding the heart. Over time, these deposits narrow the vessels and restrict blood flow. When the blockage becomes severe enough, it can trigger a heart attack or acute coronary syndrome, a medical emergency that can be fatal.
For decades, the medical focus has been on low-density lipoprotein cholesterol, or LDL-C—the "bad" cholesterol that circulates in the bloodstream. Doctors measure it, patients take statins to lower it, and the strategy has saved countless lives. But a new study published in the Journal of Lipid Research suggests the picture is incomplete. Helena Gylling and her team at the University of Helsinki examined patients who had already suffered acute coronary syndrome and found something striking: among those with high genetic cholesterol absorption efficiency, the risk of coronary artery disease was significantly elevated compared to patients with low absorption efficiency. The difference persisted even when accounting for other known risk factors.
What this means is that some people's bodies are simply better at pulling cholesterol from food and moving it into the bloodstream. This trait is written into their DNA. For most people, this might be neutral or even beneficial. But for those genetically predisposed to absorb cholesterol efficiently, the constant influx of additional cholesterol appears to accelerate the formation of arterial plaques and increase the likelihood of a heart attack.
The study also confirmed what doctors already knew: patients who took statins consistently saw better outcomes. Statins work by blocking the liver's ability to produce cholesterol, thereby lowering LDL-C levels in the blood. But the Helsinki researchers suggest this may not be enough for everyone. For patients with high cholesterol absorption efficiency, statins alone may leave them vulnerable.
The implication is both straightforward and significant. Beyond prescribing statins, doctors could identify which patients have high cholesterol absorption efficiency—a trait that can be measured through biomarkers—and treat them with additional medications designed to block cholesterol absorption in the intestines. These drugs work through a different mechanism than statins and could provide complementary protection. For a patient at high genetic risk, this dual approach might prevent the progression from healthy arteries to disease, or stop a first heart attack from becoming a fatal one.
The research opens a door to more personalized medicine in cardiovascular care. Rather than a one-size-fits-all approach based on LDL-C numbers alone, doctors could soon tailor treatment based on how efficiently a patient's body absorbs dietary cholesterol. For people with the genetic misfortune of efficient absorption, this targeted intervention could be the difference between a long life and a shortened one.
Notable Quotes
Among patients with acute coronary syndrome, those with high cholesterol absorption efficiency had a higher risk of coronary artery disease compared with those with low absorption efficiency— Helena Gylling, University of Helsinki
The Hearth Conversation Another angle on the story
So this is saying that some people's bodies are just better at absorbing cholesterol from food?
Exactly. It's a genetic trait. Some people's intestines are very efficient at pulling cholesterol out of what they eat and moving it into the bloodstream. Others are not.
And that efficiency itself—independent of how much cholesterol is actually in the blood—increases heart disease risk?
That's what the Helsinki study found. Even when you control for LDL-C levels, people with high absorption efficiency had higher coronary artery disease risk. The constant influx seems to matter.
But statins still help these people?
Yes, statins lower the amount of cholesterol the liver produces, which helps. But the researchers suggest it may not be enough if your body is also very efficient at absorbing dietary cholesterol.
So the idea is to block absorption as well as production?
Right. Use statins to reduce what the liver makes, and use absorption-blocking drugs to reduce what the intestines take in. Two different mechanisms, working together.
How would a doctor know if someone has high absorption efficiency?
It can be measured through biomarkers. That's the practical piece—identifying who needs this dual approach before they have a heart attack.